Antibody Fragments Market Report 2025

The antibody fragments market size has grown strongly in recent years. It will grow from $10.35 billion in 2024 to $11.26 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to rise in prevalence of chronic diseases, increasing adoption of biologics, growth in cancer therapeutics, regulatory approvals for antibody-based treatments, and expansion of biopharmaceutical research.

The antibody fragments market size is expected to see strong growth in the next few years. It will grow to $16.08 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing research and development investment in biologics, growing preference for smaller antibody formats, rising demand for personalized medicine, expanding applications in autoimmune diseases, and emergence of bispecific antibodies. Major trends in the forecast period include integration with AI-driven drug discovery, development of cost-effective production methods, collaborations between biotech firms, advancements in monoclonal antibody technology, and focus on antibody-drug conjugates.

The forecast of 9.3% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for diagnostic manufacturers by increasing costs of Fab and scFv fragments imported from Denmark and Belgium, potentially reducing immunoassay development capabilities and raising medical test kit production costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of target diseases is expected to drive the growth of the antibody fragments market in the coming years. Target diseases refer to specific conditions or illnesses that medical treatments, therapies, or research aim to prevent, manage, or cure. Common target diseases include cancer, infectious diseases, and bacterial infections. The increasing prevalence of these diseases is primarily attributed to unhealthy lifestyles and pollution, which weaken the body's defenses and contribute to chronic health issues. Antibody fragments offer highly specific, targeted, and versatile treatment options for a variety of diseases, often with fewer side effects compared to traditional therapies. Their ability to be tailored and engineered for specific targets makes them an invaluable tool in modern medicine. For example, in January 2025, the American Cancer Society, a U.S.-based nonprofit organization, reported that in 2025, the United States is expected to see 2,041,910 new cancer cases and 618,120 cancer-related deaths, up from 2,001,140 new cases and 611,720 deaths in 2024. Thus, the growing prevalence of target diseases is fueling the antibody fragments market's expansion.

Leading companies in the antibody fragments market are focusing on conducting clinical trials to develop innovative products, such as human VH antibody fragments, to improve the effectiveness of targeted therapies and reduce immunogenicity when treating cancers, autoimmune disorders, and infectious diseases. A human VH antibody fragment is the variable domain of the heavy chain of a human antibody, capable of binding to antigens independently. It forms antibody fragments by serving as the crucial antigen-binding region and is often used alone or in combination with other molecules to create small, stable, high-affinity therapeutic or diagnostic antibodies. For instance, in May 2024, Zai Lab Limited, a China-based pharmaceutical company, initiated a global Phase 2 clinical trial to assess the efficacy and safety of ZL-1102, a novel human VH antibody fragment (Humabody) targeting IL-17. This treatment is being developed as a topical therapy for mild-to-moderate chronic plaque psoriasis, aimed at improving treatment precision while minimizing systemic side effects and immunogenic responses.

In September 2024, Valerio Therapeutics S.A., a clinical-stage biotechnology company based in France, acquired Emglev Therapeutics for an undisclosed sum. This acquisition enhances Valerio Therapeutics' antibody discovery capabilities by incorporating Emglev Therapeutics' synthetic single-domain antibody (sdAb) technology, further expanding its therapeutic applications. Emglev Therapeutics is a biotechnology firm based in France, specializing in the development of synthetic single-domain antibodies (sdAb).

Major players in the antibody fragments market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Bio-Rad Laboratories Inc., Genmab A/S, WuXi Biologics Co. Ltd., Abcam plc, MacroGenics Inc., Harbour BioMed, Creative Biolabs Inc.

North America was the largest region in the antibody fragments market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antibody fragments report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the antibody fragments market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antibody fragments market consists of revenues earned by entities by providing services such as pharmacokinetics and toxicology testing, clinical and regulatory support services, custom conjugation services, and antibody fragment production and expression services. The market value includes the value of related goods sold by the service provider or included within the service offering. The antibody fragments market also includes sales of diabodies and tribodies, nanobodies, antibody-based therapeutics, and diagnostic agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The antibody fragments market research report is one of a series of new reports that provides antibody fragments market statistics, including the antibody fragments industry global market size, regional shares, competitors with the antibody fragments market share, detailed antibody fragments market segments, market trends, and opportunities, and any further data you may need to thrive in the antibody fragments industry. This antibody fragments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Antibody fragments are smaller portions of full-length antibodies that retain the ability to bind to specific antigens. These fragments are derived from antibodies and are designed to offer advantages such as greater stability, better tissue penetration, and reduced immune system reactions, making them valuable for both therapeutic and diagnostic uses.

The main types of antibody fragments include F(ab) fragments, F(ab’)₂ fragments, single-chain variable fragments (scFvs), single-domain antibody fragments (sdAbs), and other types. F(ab) fragments are specific fragments that have a single antigen-binding site, lacking the Fc region to minimize immune interactions, which enhances their use in diagnostics and therapy. Antibody fragments can be classified as either monoclonal or polyclonal antibodies based on their specificity. These fragments are administered through various methods, including intravenous (IV), subcutaneous (SC), oral, or transdermal routes. They are used for treating conditions such as cancer, immunodeficiencies, and other medical disorders. The key end users of antibody fragments include pharmaceutical companies, biotechnology firms, research institutions, diagnostic labs, and contract research organizations (CROs).

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.